This segment focuses on the design, development, and manufacturing of a comprehensive range of spinal implants and fixation systems used in various surgical procedures. These include thoracolumbar fixation systems, anterior lumbar plating systems, cervical plating systems, and interbody implants. Research and development efforts are directed towards creating innovative implant designs that enhance stability, promote fusion, and minimize complications. Technologies such as porous titanium and modular fixation systems are employed to improve patient outcomes. The segment addresses a wide range of spinal pathologies, from degenerative conditions to complex deformities, aiming to restore spinal integrity and improve patients' quality of life. Future opportunities include expanding the product portfolio with advanced materials and biomechanical designs, as well as pursuing regulatory approvals for new indications.

This segment encompasses advanced technologies and surgical solutions designed to enhance the precision, safety, and efficiency of spine surgery. Key offerings include the SafeOp Neural InformatiX System, which reduces the risk of intraoperative nerve injury, and the EOS imaging platform, which provides comprehensive pre- and post-operative imaging. Research and development activities are focused on integrating artificial intelligence and machine learning into surgical planning and navigation systems. These technologies aim to improve surgical outcomes, reduce operative time, and minimize patient morbidity. The segment addresses the growing demand for minimally invasive and personalized surgical approaches, offering surgeons advanced tools to optimize treatment strategies. Future opportunities include expanding the integration of robotics and augmented reality into surgical workflows, as well as developing predictive analytics tools to personalize patient care.

This segment focuses on the development and commercialization of biologic materials and bone graft solutions used to promote spinal fusion and bone regeneration. The product portfolio includes demineralized bone matrix, cellular bone matrix, and amniotic tissue barriers. Research and development efforts are directed towards creating novel biologic formulations that enhance osteoconductivity, osteoinductivity, and osteogenesis. These solutions aim to accelerate the healing process, improve fusion rates, and reduce the need for autograft harvesting. The segment addresses the growing demand for biologic alternatives to traditional bone grafting techniques, offering surgeons a range of options to optimize patient outcomes. Future opportunities include developing advanced cell-based therapies and gene-activated matrices to further enhance bone regeneration and spinal fusion.